U.K. Cancer Centre Begins Innovative Radiotherapy Treatment with Four Elekta Systems

STOCKHOLM--(Business Wire)--
Regulatory News:

Velindre Cancer Centre (Cardiff, Wales, U.K.) has awarded Elekta (STO:EKTAB)
with a multiple Elekta Synergy order, bringing the department`s installation to
four. All four systems will be used to facilitate Volumetric Modulated Arc
Therapy (VMAT), a treatment technique that offers shorter treatment times while
providing more precise control of the radiation dose to maximize safety to
nearby normal tissues. This latest order will see the replacement of existing
third party vendor equipment together with implementing MOSAIQ as the sole
patient information system.

Velindre Cancer Centre is the largest oncology Centre in Wales, and only
provider of non-surgical cancer services to the 1.5 million people in South East
Wales. A comprehensive cancer treatment centre, Velindre treats approximately
65,000 inpatients and 35,000 outpatients a year for all types of cancer.

"We`ve had two Elekta Synergy systems for some time now, and have decided to
order two more," says Nigel Cridland, Capital Planning and Estates Manager at
Velindre NHS Trust Headquarters. "The two existing systems will be retrofitted
to facilitate VMAT treatments, and the new ones will be VMAT-capable as well."

Velindre assembled a panel of physicians, radiotherapists, physicists and the
Centre`s purchasing group to research possible treatment systems, and Elekta
Synergy again emerged as the best choice. "Our experience with Elekta overall
has been very positive. They`ve continued to be extremely helpful, from project
management right through delivery, installation and training."

David Miles, Elekta Managing Director UK business unit said, "Velindre was with
another vendor for several years, but decided to buy two Elekta machines. The
fact they have again chosen Elekta is very pleasing."

The purchase of the new Elekta Synergy systems also include MOSAIQ management
information system, MOSAIQ Oncology PACS, Monaco radiation treatment planning
system and Active Breathing Coordinator. "We used MOSAIQ with the other vendor`s
equipment, and expect the transition to Elekta Synergy with MOSAIQ to be very
smooth," said Mr. Cridland. "The addition of Active Breathing Coordinator also
should help tremendously in our treatment of breast and lung patients." Monaco*
will be used for planning VMAT treatments on Elekta Synergy.

The new Elekta Synergy systems will be installed at Velindre in late autumn,
2009.

*Monaco VMAT is work in progress and not yet available for sale or distribution.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated state of the art tools and treatment planning systems for
radiation therapy and radiosurgery, as well as workflow enhancing software
systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare providers
and patients, Elekta aims to improve, prolong and even save patient lives,
making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000
hospitals globally, and every day more than 100,000 patients receive diagnosis,
treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is
located in Stockholm, Sweden, and the company is listed on the Nordic Exchange
under the ticker EKTAb. For more information about Elekta, please visit
www.elekta.com.

This information was brought to you by Cision http://www.cisionwire.com

Elekta AB
Lena Schattauer, Investor Relations
Tel: +46 8 587 257 22, +46 70 595 51 00
e-mail: lena.schattauer@elekta.com
or
Michelle Lee, PR Director
Tel: +1 770-670-2447
email: michelle.lee@elekta.com

Copyright Business Wire 2009